Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump

1 hour ago 3

William Temple

Mon, December 8, 2025 astatine 8:21 AM CST 4 min read

24/7 Wall St.

Abbott Laboratories (ABT) grew gross 6.9% with aesculapian devices up 14.8% to $5.45B. Abbott reaffirmed guidance for 7.5-8.0% integrated growth.
Eli Lilly (LLY) posted 54% gross maturation driven by Mounjaro ($6.52B) and Zepbound ($3.57B). Lilly raised guidance to $63.0-63.5B revenue.
Lilly’s operating borderline reached 48.3% versus Abbott’s 19.4%. Lilly trades astatine 49.5x P/E portion Abbott trades astatine 15.71x.
If you’re reasoning astir retiring oregon cognize idiosyncratic who is, determination are 3 speedy questions causing galore Americans to recognize they tin discontinue earlier than expected. instrumentality 5 minutes to learn much here

Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) conscionable reported Q3 net that item 2 fundamentally antithetic healthcare bets. Abbott delivered dependable 6.9% gross maturation anchored by aesculapian devices. Lilly posted explosive 54% gross maturation powered by its GLP-1 obesity and diabetes drugs.

Abbott's aesculapian instrumentality conception grew 14.8% to $5.45 billion. The cardiovascular portfolio drove results, with TriClip for tricuspid valve repair gaining Japan support and Navitor TAVI expanding its CE Mark successful Europe. Diabetes Care besides contributed meaningfully. Abbott met EPS estimates astatine $1.30. Diagnostics fell 6.6% arsenic COVID investigating gross disappeared. Operating income roseate 13.1% to $2.06 billion, though nett income stayed level twelvemonth implicit year.

Lilly's gross deed $17.60 billion, beating estimates by 9.5%, with Mounjaro generating $6.52 cardinal (up 109%) and Zepbound adding $3.57 cardinal (up 184%). Volume crossed the incretin portfolio surged 62%. Net income jumped 475% to $5.58 billion. Operating borderline reached 48.3%, astir treble Abbott's. CEO David Ricks highlighted advancement connected orforglipron, an oral GLP-1 campaigner that completed 4 Phase 3 trials and could alteration planetary obesity submissions by twelvemonth end. Lilly raised full-year guidance to $63.0-63.5 cardinal successful gross and $23.00-23.70 successful non-GAAP EPS. Abbott reaffirmed its outlook for 7.5-8.0% integrated maturation excluding COVID testing.

Metric	Abbott	Lilly
Revenue Growth	6.9% YoY	54% YoY
Net Income Growth	Flat (0%)	475% YoY
Operating Margin	19.4%	48.3%
Guidance	Reaffirmed	Raised

Abbott spreads hazard crossed aesculapian devices, diagnostics, nutrition, and branded generics. No azygous merchandise dominates. The institution operates successful 160 countries with vulnerability to cardiovascular, diabetes, and structural bosom markets. This operation limits upside but cushions downside.

Lilly has placed an tremendous stake connected incretin-based therapies. Mounjaro and Zepbound present relationship for implicit $10 cardinal successful quarterly gross combined. The institution is expanding manufacturing capableness successful Virginia, Texas, and Puerto Rico to conscionable demand. Return connected equity sits astatine 96.5%. But attraction creates vulnerability. If GLP-1 request softens oregon contention intensifies, Lilly's maturation trajectory changes immediately.